Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 9, 2014, Pages 1699-1705

  Shim, Jae Jun ^a   Kim, Jung Wook ^a   Lee, Chang Kyun ^a   Jang, Jae Young ^a   Kim, Byung Ho ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Alpha fetoprotein; Antiviral therapy; Chronic hepatitis B; Hepatocellular carcinoma

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CLEVUDINE; GUANINE; URACIL ARABINOSIDE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TIME;

ADMINISTRATION, ORAL; ADULT; AGED; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84906513033     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12612     Document Type: Article

References (42)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533-543.
2. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 2009; 24: 346-353.
3. Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig. Dis. 2001; 19: 263-268.
4. Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J. Hepatol. 2009; 15 (Suppl. 6): S50-59.
5. Kim H, Shin AR, Chung HH etal. Recent trends in hepatitis B virus infection in the general Korean population. Korean J. Intern. Med. 2013; 28: 413-419.
6. Korean Liver Cancer Study Group and National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009; 15: 391-423.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
8. Kudo M, Izumi N, Kokudo N etal. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 2011; 29: 339-364.
9. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
10. Singal A, Volk ML, Waljee A etal. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment. Pharmacol. Ther. 2009; 30: 37-47.
11. Snowberger N, Chinnakotla S, Lepe RM etal. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment. Pharmacol. Ther. 2007; 26: 1187-1194.
12. Trinchet J-C, Chaffaut C, Bourcier V etal. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997.
13. Wong CR, Garcia RT, Trinh HN etal. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig. Dis. Sci. 2009; 54: 2712-2721.
14. Davila JA, Henderson L, Kramer JR etal. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann. Intern. Med. 2011; 154: 85-93.
15. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
16. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. alpha-fetoprotein in noneoplastic hepatic disorders. JAMA 1975; 233: 38-41.
17. Alpert E, Feller ER. Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 1978; 74: 856-858.
18. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6: 133-137.
19. Singal AG, Conjeevaram HS, Volk ML etal. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol. Biomarkers Prev. 2012; 21: 793-799.
20. Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin. Gastroenterol. Hepatol. 2013; 11: 437-440.
21. Yao FY. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J. Clin. Gastroenterol. 2003; 36: 440-442.
22. Chen TM, Huang PT, Tsai MH etal. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J. Gastroenterol. Hepatol. 2007; 22: 669-675.
23. Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J. Viral Hepat. 2010; 17: 511-517.
24. Asahina Y, Tsuchiya K, Nishimura T etal. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253-1262.
25. Trevisani F, D'Intino PE, Morselli-Labate AM etal. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001; 34: 570-575.
26. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. Serum alpha-fetoprotein in patients with massive hepatic necrosis. Gastroenterology 1977; 72: 479-492.
27. Karvountzis GG, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Ann. Intern. Med. 1974; 80: 156-160.
28. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41: 26-31.
29. Lee IC, Huang Y-H, Chan C-C etal. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of α-fetoprotein. Liver Int. 2010; 30: 1161-1168.
30. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol. 2004; 99: 860-865.
31. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
32. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
33. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin. Mol. Hepatol. 2012; 18: 109-162.
34. Eleftheriou N, Heathcote J, Thomas HC, Sherlock S. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. J. Clin. Pathol. 1977; 30: 704-708.
35. Seto WK, Lai CL, Ip PP etal. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS ONE 2012; 7: e32622.
36. Sanai FM, Babatin MA, Bzeizi KI etal. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen-negative patients with chronic hepatitis. Clin. Gastroenterol. Hepatol. 2013; 11: 1493-9 e2.
37. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in "real-life" settings: from clinical trials to clinical practice. J. Viral Hepat. 2012; 19: 377-386.
38. Chang T-T, Liaw Y-F, Wu S-S etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
39. Marcellin P, Gane E, Buti M etal. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
40. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
41. Hosaka T, Suzuki F, Kobayashi M etal. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
42. Wong GL, Chan HL, Tse YK etal. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014; 59: 986-995.